Mereo BioPharma Group plc Cash Flow Statement
MREO|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Mereo BioPharma Group plc used $31M in operating cash flow and negative free cash flow of $31M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$41.9M | -$43.3M | -$29.5M |
| Operating Cash Flow | -$31.0M | -$32.8M | -$21.1M |
| Capital Expenditures | $20.0K | $0 | $0 |
| Free Cash Flow | -$31.0M | -$32.8M | -$21.1M |
| FCF Margin | -6198.2% | - | -211.3% |